Clinical trials in Corbeil Essonnes – page 28

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Acute myocardial infarction

Recruiting

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adenosine
Sponsor:Corflow Therapeutics AG

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ficerafusp alfa
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Pericarditis

Recruiting

A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis

InvestigationalNo placebo

France

Participants:65+ years
Substances:VTX2735 sodium
Sponsor:Zomagen Biosciences Limited

Contact Research Centre

Peripheral arterial occlusive disease

Recruiting

A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease

Investigational

A study to evaluate the efficacy and safety of orforglipron in patients with peripheral artery disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Orforglipron hemicalcium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Orforglipron hemicalcium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Colitis ulcerative

Recruiting

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo

France

Participants:0–17 years
Sponsor:Pfizer Inc.

Contact Research Centre

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo

France

Participants:0–17 years
Substances:Lonapegsomatropin
Sponsor:Ascendis Pharma Endocrinology Division A/S

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Fungal infection

Recruiting

A study to compare the effectiveness of EL219 against liposomal amphotericin B and voriconazole for patients with suspected invasive mould infections.

Registered drug

A study to compare the effectiveness of EL219 against liposomal amphotericin B and voriconazole for patients with suspected invasive mould infections.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Amphotericin B
Sponsor:Elion Therapeutics Inc.

Contact Research Centre

Cerebral haemorrhage

Recruiting

A study to evaluate the use of diroximel fumarate to reduce brain swelling in patients with a stroke caused by bleeding in the brain.

Registered drug

A study to evaluate the use of diroximel fumarate to reduce brain swelling in patients with a stroke caused by bleeding in the brain.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Diroximel Fumarate
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Neoplasm malignant

Recruiting

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:DS-3790A
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

HIV infection

Recruiting

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries